First-in-class small molecule candidate NCGC72 (CD206 agonist) for immunologically cold solid organ cancers
Ended Awarded Last action
- Contract number
- 75N95024F00002
- Awardee
-
IIT Research Institute UEI DGBUFQYMKWB5 Part of Illinois Institute Of Technology
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $547,006
Award facts
- Opportunity
-
- 75N95024R00117 Solicitation number
- Contract value 100% obligated
- $547,006.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 4 offers Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Chicago, IL 60616, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $34,740 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $512,266 |
About this award
The National Institute on Drug Abuse issued a delivery order to IIT Research Institute on September 18, 2024, for preclinical development of NCGC72, a CD206 agonist candidate for immunologically cold solid organ cancers, with a ceiling value of $547,006 under a cost-plus-fixed-fee pricing structure.
The order is issued under the Safety Evaluation and Toxicology Studies and Related Services for Drug Development IDIQ, a multiple-award vehicle supporting in vitro and in vivo exploratory and IND-directed toxicology studies. Place of performance is Chicago, IL. Ultimate completion is December 31, 2025.
IIT Research Institute is a non-profit contract research organization and wholly-owned subsidiary of Illinois Institute of Technology. The organization conducts preclinical toxicology and pharmacokinetic studies in support of investigational new drug development across therapeutic areas including oncology, infectious diseases, and neurological disorders.
In FY2025, the order generated $493,000 in invoiced federal services with 1.2 FTEs of delivery. The prime self-performed all reported hours with no subcontractor involvement.
Quick answers
Who was awarded contract 75N95024F00002?
75N95024F00002 was awarded to IIT Research Institute by National Institute on Drug Abuse (National Institutes of Health) on September 18, 2024.
How much is contract 75N95024F00002 worth?
The government has obligated $547,006 on 75N95024F00002.
Is contract 75N95024F00002 an order under another contract?
Yes. 75N95024F00002 is a delivery order under 75N95024D00020, an indefinite delivery contract, on Safety Evaluation and Toxicology Studies and Related Services for Drug Development.
Was contract 75N95024F00002 competed?
The extent of competition for 75N95024F00002 was full and open competition. The government received 4 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award